With its Italian roots and global reach, Kedrion is one of the FAB13, the historic Italian companies of Made in Italy pharmaceuticals, part of Farmindustria.<\/p>\n\n\n\n
The latest Report on the FAB13 published by the Edison Foundation was presented today in Milan, confirming that the 13 companies that have their \u201cheart and brain\u201d in our country are growing and continue to represent the engine of the national economy.<\/p>\n\n\n\n
As reported in the press release, the presentation analyzed the results achieved by the Italian pharmaceutical industry in the last 20 years in terms of growth in production, employment, research and development, innovation and export.<\/p>\n\n\n\n
The Italian pharmaceutical industry stands out as one of the driving sectors of Made in Italy, and the FAB13 \u2013 which, in addition to Kedrion, include Alfasigma, Abiogen Pharma, Angelini Pharma, Chiesi Farmaceutici, Domp\u00e9 Farmaceutici, I.B.N. Savio, Italfarmaco, Menarini, Molteni, Neopharmed Gentili, Recordati and Zambon \u2013 confirm their central role in innovation, research and the economic growth of the country.<\/p>\n\n\n\n
According to the Report, these companies recorded a total turnover of 16.8 billion Euro in 2023, of which 12.8 billion Euro were generated on the foreign market (76% of total turnover), while maintaining strategic and decision-making direction in Italy. Also in 2023, the FAB13 invested over 1 billion Euro in Research & Development, a 12% increase compared to the previous year. These investments demonstrate the companies’ commitment to developing innovative medicines, personalized therapies and treatments for rare diseases.<\/p>\n\n\n\n
The Report also highlights some key needs for the future of the sector. These include increased communication with decision makers to raise awareness of the strategic value of pharmaceuticals, a clearer and more stable regulatory system that encourages investment and reduces bureaucracy, strengthening patent protection to protect innovation and attract new investments in research, and reducing tax pressure by creating incentives to make Italy a reference hub for pharmaceuticals.<\/p>\n\n\n\n
The presentation also highlighted the need to support research on orphan drugs and innovative therapies, to improve the synergy between universities and businesses to train and retain talent in the scientific sector and to simplify the procedures for approval and access to drugs, with particular attention to reducing regional disparities.<\/p>\n\n\n\n
In-depth overview of FAB13 Report and the role of companies<\/strong><\/p>\n\n\n\n The “FAB13” Report from the Edison Foundation<\/strong> provides a comprehensive analysis of the Italian pharmaceutical industry, focusing on 13 historic companies that have significantly contributed to the sector’s growth. These companies, including Kedrion Biopharma, are recognized for their ability to combine tradition and innovation, maintaining a strong international presence while keeping strategic direction in Italy.<\/p>\n\n\n\n Growth and internationalization<\/strong><\/p>\n\n\n\n From 2016 to 2023, the FAB13 recorded a revenue growth of 60%, reaching 16.8 billion Euro. Of this, 12.8 billion Euro comes from foreign markets, highlighting the importance of internationalization. Exports amount to 6.2 billion Euro, representing 13% of total Italian pharmaceutical exports.<\/p>\n\n\n\n Investments in Research and Development<\/strong><\/p>\n\n\n\n In 2023, the FAB13 collectively invested 3.4 billion Euro, of which over 1 billion Euro was allocated to research and development, marking a 12% increase compared to the previous year. An additional 1.7 billion Euro was used for strategic acquisitions and licenses aimed at strengthening global competitiveness.<\/p>\n\n\n\n Employment impact<\/strong><\/p>\n\n\n\n These companies employ approximately 47,200 people, with over 14,800 in Italy. 67% of employees have permanent contracts, while 54% work in research and development and production. 80% of the workforce holds a degree or diploma, emphasizing the high qualification required in the sector.<\/p>\n\n\n\n Tax contribution and requests to Institutions<\/strong><\/p>\n\n\n\n Despite international expansion, the FAB13 consolidate their balances in Italy, significantly contributing to the national tax system and funding public healthcare. To maintain and enhance this growth, companies emphasize the need for a stable and clear regulatory framework, incentives for research and innovation, greater patent protection, and reduced bureaucracy to facilitate investments.<\/p>\n\n\n\n In summary, the report highlights how companies like Kedrion Biopharma<\/strong> are fundamental to the Italian economy, combining a strong tradition with an innovative and international vision.<\/p>\n","protected":false},"featured_media":8284,"template":"","categories_news":[],"class_list":["post-8285","news","type-news","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n